Cat. #161809
PC346C Cell line
Cat. #: 161809
Availability: 8-10 weeks
Organism: Human
Tissue: Transurethral resection of the prostate (TURP)
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Wytske van Weerden
Institute: Erasmus University Medical Centre
Primary Citation: Marques et al. 2006. Eur Urol. 49(2):245-57. PMID: 16413664 ; Marques et al. 2010. PLoS One. 5(10):e13500. PMID 20976069 ; Marques et al. 2005. Int J Cancer. 117(2):221-229. PMID 15900601.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: PC346C Cell line
- Cancer: Genitourinary cancer
- Research fields: Cancer
- Organism: Human
- Gender: Male
- Tissue: Transurethral resection of the prostate (TURP)
- Description: Prostate cancer cell line derived from PDX (from transurethral resection of a primary prostate tumour); AR+, PSA+
- Biosafety level: 2
Handling
- Format: Frozen
- Volume: 1 ml
- Growth medium: Prostate growth medium (PGM): DMEM-F12, 1X insulin-transferrin-selenium, 100 ng/mL fibronectin, 20 μg/mL fetuin, 0.01% BSA, 10 ng/mL epidermal growth factor, 50 ng/mL cholera toxin, 100µM phosphorylethanolamine, 0.6 ng/mL triiodothyronine, 0.1nM R1881, 10μM Y-27632 dihydrochloride, 0.5 µg/mL hydrocortisone and penicillin/streptomycin antibiotics (100 U/mL penicillin, 100 μg/mL streptomycin). Supplemented with 2% FCS.
- Temperature: 37° C
- Atmosphere: 5% CO2
- Shipping conditions: Dry ice
- Storage medium: PGM+20S+7.5% DMSO
- Storage conditions: Liquid Nitrogen
- Initial handling information: Protocols/SOPs available from inventor
- Cultured in antibiotics: Penicillin/Streptomycin 1%
